fda pulling semaglutide Hims & Hers Pulls Access to Compounded Pill Following Controversial Launch US judge upholds FDA's removal

Kevin M

North Carolinians who join us know that results are not just possiblethey are happening now

Multiple technological generationsincluding enteric coatings, protease inhibitors, permeation enhancers, lipid-based systems, polymeric nanoparticles, and mucoadhesive formulationshave been developed to address gastrointestinal degradation and epithelial impermeability, yet none have reliably produced predictable systemic exposure suitable for regulatory approval ( The recent approval of oral semaglutide represents the first unequivocal demonstration that a systemically acting peptide can be administered orally at a commercial scale with reproducible clinical benefit ( Historically, nearly every major therapeutic peptide class has been evaluated for oral delivery

(1) Dapagliflozin when used as a component of XIGDUO XR, is indicated in adults with type 2 diabetes mellitus to reduce the risk of: Sustained eGFR decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in patients with chronic kidney disease at risk of progression